Caris Presents Rare Gene Fusion Research at AMP

Two posters from Caris Life Sciences detail novel fusions found across hundreds of thousands of solid tumors.

Updated on Nov. 16, 2026 in Cancer

Sealed glass genomic sequencing instrument with chrome fittings on a clean laboratory bench beside a rack of sample tubes.
Caris Life Sciences presented two posters at the Association for Molecular Pathology 2026 Annual Meeting detailing rare gene fusions found across hundreds of thousands of solid tumors. AI Illustration. Upload story photo >

Caris Life Sciences presented two posters at the Association for Molecular Pathology 2026 Annual Meeting. The research centers on novel and rare gene fusions identified through Whole Transcriptome Sequencing.

Why it matters

Gene fusions can drive cancer growth and may point to targeted treatment options, so identifying uncommon fusions across large tumor datasets can help map which patients might respond to matched therapies. The work adds to a growing body of molecular profiling aimed at expanding the options available beyond common alterations.

The research draws on Whole Transcriptome Sequencing applied to 698,406 solid tumors, a dataset used to find new and rare fusions. The stub does not provide outcome comparisons or prevalence figures, and the full abstracts are available on the Caris website.

The players

Caris Life Sciences

Caris Life Sciences is an Irving, Texas-based company focused on molecular profiling and precision oncology diagnostics that presented the research.

George W. Sledge, Jr., MD

George W. Sledge, Jr., MD is a physician and oncologist who serves as Executive Vice President and Chief Medical Officer of Caris Life Sciences.

The details

One study examined gene fusions across a broad pan-cancer cohort and evaluated outcomes tied to matched therapies, including analyses in non-small cell lung cancer and cholangiocarcinoma. A second poster characterized rare PAK-family gene fusions in ovarian, fallopian tube and primary peritoneal serous carcinomas.

Timeline

  1. 2026: Caris presents two posters at the Association for Molecular Pathology 2026 Annual Meeting.

  2. November 16, 2026: Caris announces the poster presentations via press release.

  3. March 3, 2026: Caris files its Annual Report on Form 10-K with the SEC.

Health Landscape

The research extends whole transcriptome profiling, which reads RNA across the genome, from detecting established alterations toward mapping uncommon fusions that conventional DNA-based panels can miss. This shift reflects a broader move in oncology toward molecular testing that informs treatment selection across tumor types rather than by organ alone.

For patients with cancer, the research points toward testing that looks beyond common mutations, which may matter when standard options have been exhausted. Any clinical use would depend on whether matched therapies are approved or enrolled in trials, so patients should discuss molecular testing options with their oncologist.

The takeaway

Molecular profiling at large scale is uncovering rare gene fusions that may open treatment paths for patients whose tumors lack common alterations. Patients and families can ask their care team whether broader genomic testing is appropriate.

Further reading

For more on how genetic testing shapes cancer treatment, explore the Cancer section.

Source note: This article includes information reported by Star Local.